- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Erythromelalgia, Inherited Erythromelalgia
- Interventions
- XPF-002, Placebo
- Drug
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Industry
- Eligibility
- 19 Years to 80 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Anniston, Alabama
- Conditions
- Migraine Prophylaxis
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Long Beach, California • San Diego, California + 26 more
- Conditions
- Exercise-induced Muscle Soreness, Exercise-induced Joint Pain, Exercise-induced Joint Stiffness, Exercise-induced Cartilage Turnover
- Interventions
- NEM® brand eggshell membrane powder, curQ+® brand highly absorbable curcumin, EM Placebo, Curc Placebo, NEM® plus curQ+® combination
- Dietary Supplement
- Lead sponsor
- ESM Technologies, LLC
- Industry
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Erythromelalgia
- Interventions
- Amitriptyline Hydrochloride, Placebo
- Drug
- Lead sponsor
- AlgoTherapeutix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Migraine
- Interventions
- Fremanezumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,890 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
- Conditions
- Schizophrenia
- Interventions
- 1 Hz rTMS Stimulation, Sham rTMS Stimulation
- Device
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Episodic Migraine, Chronic Migraine
- Interventions
- Corabotase, Placebo, Corabotase dose A, Corabotase dose B
- Biological · Other
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 51 more
- Conditions
- Fragile X Syndrome
- Interventions
- 5-Hydroxytryptophan, Ergoloid Mesylates, Matching placebo for Ergoloid mesylates, Matching placebo for 5-Hydroxytryptophan
- Drug
- Lead sponsor
- Elizabeth Berry-Kravis
- Other
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois